18 results on '"Dorsch, Marion"'
Search Results
2. Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)
3. Abstract 1279: Development of a selective CDK2-E inhibitor in CCNE driven cancers
4. Abstract 1717: MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models
5. Abstract 3116: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model
6. Abstract 1194: IDH1 mutant inhibitor induces cellular differentiation and offers a combination benefit with Ara-C in a primary human Idh1 mutant AML xenograft model
7. Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition
8. Abstract 4376: Evaluation of PRP4 kinase as a potential drug target in cancer.
9. Abstract 4406: CARD11 is critical for in vitro and in vivo growth of ABC-DLBCL cells.
10. Abstract 4553: Design and validation of a screening strategy for the identification of novel inhibitors of wild type and mutant CARD11 mediated BCR/NF-κB signaling.
11. Abstract 1135: Chemical Proteomics effort identifies PKN1 as a key player in the canonical NF-κB signaling pathway.
12. Abstract 1796: SAR302503: A Jak2 inhibitor with antitumor activity in solid tumor models
13. The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells
14. Abstract 4290: The smoothened antagonist NVP-LDE225 targets stroma and cancer stem cells in primary human pancreatic tumor xenografts
15. Abstract 1976: The discovery of mechanisms of resistance to SMO antagonists and the therapeutic implications
16. Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials
17. PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
18. A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.